Reducing the risks of distortion in cannabis research

Editorial

. 2020 May;115(5):799-801.

doi: 10.1111/add.14801. Epub 2019 Nov 6.

Keith Humphreys^{1

2

3}, Wayne D Hall^{4

3}

Affiliations

¹ Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
² Stanford University, Stanford, CA, USA.
³ National Addiction Centre, King's College London, London, UK.
⁴ The University of Queensland Centre for Youth Substance Abuse Research, St Lucia, QLD, Australia.

Editorial

Keith Humphreys et al. Addiction. 2020 May.

. 2020 May;115(5):799-801.

doi: 10.1111/add.14801. Epub 2019 Nov 6.

Keith Humphreys^{1

2

3}, Wayne D Hall^{4

3}

¹ Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
² Stanford University, Stanford, CA, USA.
³ National Addiction Centre, King's College London, London, UK.
⁴ The University of Queensland Centre for Youth Substance Abuse Research, St Lucia, QLD, Australia.

No abstract available

Response to Humphreys & Hall (2020): Reducing the risks of distortion in cannabis research.
Hamilton I. Hamilton I. Addiction. 2020 Dec;115(12):2408-2409. doi: 10.1111/add.15157. Epub 2020 Jul 3. Addiction. 2020. PMID: 32533739 No abstract available.

Similar articles

Vested interests in addiction research and policy. The challenge corporate lobbying poses to reducing society's alcohol problems: insights from UK evidence on minimum unit pricing.
McCambridge J, Hawkins B, Holden C. McCambridge J, et al. Addiction. 2014 Feb;109(2):199-205. doi: 10.1111/add.12380. Epub 2013 Nov 21. Addiction. 2014. PMID: 24261642 Free PMC article. Review.
Response to Humphreys & Hall (2020): Reducing the risks of distortion in cannabis research.
Hamilton I. Hamilton I. Addiction. 2020 Dec;115(12):2408-2409. doi: 10.1111/add.15157. Epub 2020 Jul 3. Addiction. 2020. PMID: 32533739 No abstract available.
Ethics, morality, and conflicting interests: how questionable professional integrity in some scientists supports global corporate influence in public health.
Baur X, Budnik LT, Ruff K, Egilman DS, Lemen RA, Soskolne CL. Baur X, et al. Int J Occup Environ Health. 2015;21(2):172-5. doi: 10.1179/2049396714Y.0000000103. Epub 2015 Mar 2. Int J Occup Environ Health. 2015. PMID: 25730664 Free PMC article.
Six policy lessons relevant to cannabis legalization.
Shover CL, Humphreys K. Shover CL, et al. Am J Drug Alcohol Abuse. 2019;45(6):698-706. doi: 10.1080/00952990.2019.1569669. Epub 2019 Mar 14. Am J Drug Alcohol Abuse. 2019. PMID: 30870053 Free PMC article. Review.
Conflict of interests, vested interests and health research.
Little M. Little M. J Eval Clin Pract. 2000 Nov;6(4):413-20. doi: 10.1046/j.1365-2753.2000.00246.x. J Eval Clin Pract. 2000. PMID: 11133124

1. Caputi T. L. Medical marijuana, not miracle marijuana: some well-publicized studies about medical marijuana do not pass a reality check. Addiction 2019; 114: 1128-1129.
1. Bachhuber M. A., Saloner B., Cunningham C. O., Barry C. L. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med 2014; 174: 1668-1673.
1. Alcántara A. Weedmaps wants to drive the conversation on marijuana with hundreds of billboards: installlations show positive facts about pot usage. Adweek 2018; May 7. Available at: https://www.adweek.com/digital/weedmaps-wants-to-drive-the-conversation-... (accessed 25 July 2019).
1. Lewis A. Medical pot is our best hope to fight the opioid epidemic: ‘There are direct reasons why [cannabis] could actually help people get off of opioids,’ says one leading marijuana researcher. Rolling Stone 2017; 8 December. Available at: https://www.rollingstone.com/culture/culture-news/medical-pot-is-our-bes... (accessed 25 July 2019).
1. Hall W. D., West R., Marsden J., Humphreys K., Neale J., Petry N. It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis. Addiction 2018; 113: 987-988.